Back to results
US 2024/0181019 A1Published application
Use of ultrarapid acting insulin
AssigneeMannKind Corporation
InventorsAnders Hasager Boss, Richard Petrucci
Life of this patent
Estimating the term…
Abstract
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Claims19
A method of treating hyperglycemia in a patient with a Body Mass Index (BMI) of over 25 kg/m2;
- the method comprising:
- administering by inhalation an initial dose of an ultra rapid acting insulin formulation taken at mealtime and a second dose of between 10% to 100% of said initial dose taken 30 to 150 minutes after beginning the meal.
Dependencies are inferred from the claim text.